**Positive Phase 3 results from the INTerpath-001 trial announced August 19, 2026, represent the main catalyst behind strong trader sentiment for a BLA submission by mid-2027.** Moderna and Merck reported that their individualized mRNA neoantigen therapy intismeran autogene (mRNA-4157/V940), combined with Keytruda (pembrolizumab), achieved statistically significant and clinically meaningful improvements in recurrence-free survival and distant metastasis-free survival versus Keytruda alone in patients with resected high-risk stage IIB-IV melanoma. This marks the first positive late-stage readout for an mRNA-based personalized cancer vaccine. The companies stated they will present full data at an upcoming medical meeting and engage regulators on filing submissions, building on five-year Phase 2 follow-up showing a sustained 49% reduction in recurrence or death risk. With breakthrough therapy designation and a typical six-to-eight-week personalized manufacturing timeline, traders see a clear path to a 2026 or early 2027 BLA, though detailed efficacy numbers, safety data, and any FDA feedback on accelerated review remain key swing factors.